Risk of Type 2 Diabetes Is Lower in US Adults Taking Chromium-Containing Supplements.
BACKGROUNDDietary supplement use is widespread in the United States. Although it has been suggested in both in vitro and small in vivo human studies that chromium has potentially beneficial effects in type 2 diabetes (T2D), chromium supplementation in diabetes has not been investigated at the population level.
OBJECTIVEThe objective of this study was to examine the use and potential benefits of chromium supplementation in T2D by examining NHANES data.
METHODSAn individual was defined as having diabetes if he or she had a glycated hemoglobin (HbA1c) value of ≥6.5%, or reported having been diagnosed with diabetes. Data on all consumed dietary supplements from the NHANES database were analyzed, with the OR of having diabetes as the main outcome of interest based on chromium supplement use.
RESULTSThe NHANES for the years 1999-2010 included information on 62,160 individuals. After filtering the database for the required covariates (gender, ethnicity, socioeconomic status, body mass index, diabetes diagnosis, supplement usage, and laboratory HbA1c values), and when restricted to adults, the study cohort included 28,539 people. A total of 58.3% of people reported consuming a dietary supplement in the previous 30 d, 28.8% reported consuming a dietary supplement that contained chromium, and 0.7% consumed supplements that had "chromium" in the title. Compared with nonusers, the odds of having T2D (HbA1c ≥6.5%) were lower in persons who consumed chromium-containing supplements within the previous 30 d than in those who did not (OR: 0.73; 95% CI: 0.62, 0.86; P = 0.001). Supplement use alone (without chromium) did not influence the odds of having T2D (OR: 0.89; 95% CI: 0.77, 1.03; P = 0.11).
CONCLUSIONSOver one-half the adult US population consumes nutritional supplements, and over one-quarter consumes supplemental chromium. The odds of having T2D were lower in those who, in the previous 30 d, had consumed supplements containing chromium. Given the magnitude of exposure, studies on safety and efficacy are warranted.
Boston Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA; and email@example.com.,
Harvard Medical School, Boston, MA; and Joslin Diabetes Center, Boston, MA.,
Boston Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA; and.
Harvard Medical School, Boston, MA; and Joslin Diabetes Center, Boston, MA.
Diabetes Mellitus, Type 2
Glycated Hemoglobin A
Pub Type(s)Journal Article
Research Support, N.I.H., Extramural